|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent findings highlight the importance of TNFR2 as a key regulator of activated natural FoxP3<sup>+</sup> regulatory T cells (Tregs) in inflammatory conditions, such as acute graft-vs.-host disease (GvHD) and the tumor microenvironment.
|
31555271 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TrkA and p75 showed no association with tumor grade, Fédération Internationale des Gynaecologistes et Obstetristes stage, chemotherapy status, the extent of residual disease, or survival (P > 0.05).
|
11705863 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We summarize the recent progress in understanding how TNFR2-dependent mechanisms promote carcinogenesis and tumor growth and discuss the potential value of TNFR2 in cancer treatment.
|
29892300 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Concentrations of tumor nuclear factor-receptor 2 (TNF-R2), e-selectin, and endostatin were significantly lower after consumption of the RP diet compared with WP (p < 0.05).
|
30685298 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, p75 expression was less frequent in effusions compared to both primary tumors and lymph node metastases, significantly so for the latter (p = 0.019).
|
14997042 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Clinical Relevance of a Candidate Stem Cell Marker, p75 Neurotrophin Receptor (p75NTR) Expression in Circulating Tumor Cells.
|
28560678 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TNFR2 expression (P=0.017), age (P=0.011), menopausal status (P<0.0001), tumor size (P=0.016), clinical stage (P=0.005), pathological grade (P=0.002) and estrogen/progesterone receptor and HER2 triple-status (P=0.008) were all shown to significantly impact the DFS rate of patients with BC.
|
28789455 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate that a certain level of expression of TNF-R75 is necessary for obtaining TNF-alpha-mediated tumor cell lysis in the absence of TNF-R75.
|
9685865 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, our results document for the first time frequent expression of p-TrkA and lower expression of p75 in MM, in agreement with the biological aggressiveness of this tumor.
|
15084380 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These TNFR2 antibodies killed T<sub>regs</sub> isolated from ovarian cancer ascites more potently than it killed T<sub>regs</sub> from healthy donor samples, suggesting that these antibodies may have specificity for the tumor microenvironment.
|
28096513 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also posit that TNFR2 inhibitors might potentially constitute safer and more targeted alternatives to ICI cancer treatment because the expression of TNFR2 on immune cells, concentrated in the tumor microenvironment of various cancers, appears to be more selective than that of checkpoint molecules.
|
29032004 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with the combination of TNFR2-blocking antibody and a CD25-targeted antibody also resulted in enhanced inhibition of tumor growth in a syngeneic 4T1 mouse model of breast cancer.
|
29295954 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TrkA and p75 were positively correlated and were respectively associated with the histoprognostic grading and the tumor type.
|
11389056 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In an unrelated cohort of 110 neuroblastic tumors, p75 mRNA expression levels correlated with differentiation, and patients with tumors that expressed p75 at high levels had an increased event-free and overall survival.
|
19142969 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types.
|
19738070 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor necrosis factor receptor 2 (TNFR2) promotes tumor cell proliferation, activates immunosuppressive cells, and supports immune escape.
|
30628200 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The interaction of tumor necrosis factor-α (TNF-α) with its receptors: TNFRSF1A and TNFRSF1B is critical for the promotion of tumor growth, invasion and metastasis.
|
25010932 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, p75 expression was substantially reduced in a subset of tumors and cell lines, in particular compared to its expression in normal retina.
|
17973327 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p75 neurotrophin receptor (p75(NTR)) functions as a tumor suppressor in prostate epithelial cells, where its expression declines with progression to malignant cancer.
|
18974393 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High expression and role of tumor necrosis factor receptor 2 (TNFR2) in cancer progression and prognosis has been reported in several types of tumors.
|
30127886 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In recent years, the role of TNFR2 has attracted much attention for its promotion role in several types of tumors.
|
29920311 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings show that cell survival genes mediated by TNF/TNFR2 binding is up-regulated in GC favoring its pro-tumoral effect, while pro-apoptotic genes as CASP3 and TNFR1 are down-regulated, indicating disbalance between apoptosis and cell proliferation processes in this neoplasm.
|
31040894 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A neurotrophin receptor p75 (p75NTR) is expressed in a candidate stem cell fraction in esophageal squamous cell carcinoma (ESCC), which shows significantly higher colony formation, enhanced tumor formation in mice, along with strong expression of epithelial mesenchymal transition-related genes.
|
28819854 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro and in vivo fluorescence imaging results suggest peptide P75 modified magnetosomes (Mag-P75) specifically bind to MDA-MB-468 and SKBR3 cells as well as xenograft tumors with surprisingly low accumulation in other organs including liver and kidney.
|
27888699 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, metastasis to the lung was observed in a few cases following development of mammary tumors in p75 CUX1 transgenic mice.
|
20224295 |
2011 |